EUCTR2020-001496-32-HU进行中（未招募）1 期
A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID) - PID-PED study
KEDRION S.P.A0 个研究点目标入组 30 人开始时间: 2020年7月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent/assent obtained from the patient and his/her parent(s) or egally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.
- •2. Confirmed clinical diagnosis of a PID as defined by 2017 International Union of Immunological Societies (IUIS) Phenotypic Classification for Primary Immunodeficiencies (Bousfiha A, 2018) and The European Society for Immunodeficiencies (ESID) Registry
- •Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (Seidel MG at al., 2019) and requiring treatment with IVIg. Documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia
- •(defined as low levels of one or more classes [ie, at least 2 standard deviations under the mean level per age]). (NOTE: IVIg treatment is generally requested in the absence of IgG independently from whether other antibodies are absent).
- •3. Male or female, age from 2 up to 16 years and 11 months, at the time of screening, as the patient must be under 18 years (< 18) at the time of study termination visit.
- •4. Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 1- or 28-day intervals (±3 or ±4 days, respectively) for at least 3 infusion cycles prior to screening. (NOTE: Other IVIgs will be prohibited after ICF signature and until study end, week 51/52).
- •5. At least 2 documented IgG trough levels while receiving an IVIg, of = 6 g/L obtained at 2 infusion cycles within 12 months (1 must be within 6 months) prior to ICF ignature.
- •6. Patient and his/her parent(s)/legal guardian(s) are willing to comply with all requirements of the protocol.
- •7. Females of child-bearing potential with a negative pregnancy test (serum or urine) and who agree to employ adequate birth control measures during the study.
- •8. Authorization to access personal health information.
- •9. Patients previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening.
- •10. Patients currently on treatment with any subcutaneous immunoglobulin (SCIG) can be nrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusion cycles (21 or 28 days) prior to screening.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 30
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Newly diagnosed PID and naïve to IgG replacement therapy.
- •Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency, or profound primary T cell deficiency (defined as the absence or severe reduction of T
- •lymphocytes [CD3+ <300 cell/mm3] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA]).
- •History of severe or serious reactions or hypersensitivity to IVIg or other injectable forms of IgG.
- •History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction, as defined by at least 1 event in patient’s lifetime.
- •IgA deficiency with documented antibodies to IgA.
- •Received blood products that have not undergone viral inactivation measures within 12 months prior to ICF signature.
- •Significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia.
- •An acute infection as documented by culture or diagnostic imaging and/or a body temperature =38.5° C (=101.3° F) within 7 days prior to screening.
- •Acquired immunodeficiency syndrome (AIDS) and/or hepatitis B/C active disease at ICF signature.
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
- •Using an implanted venous access device.
- •Profound anemia, defined according to the patient's age as shown in table Dallman PR, 1979 or persistent severe neutropenia (= 500 neutrophils per mm3) or persistent lymphopenia of less than 500 cells per microliter.
- •A severe chronic condition such as renal failure, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart
- •disease, hyperviscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
- •History of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature.
- •History of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not controlled by medication.
- •Patient must not be receiving the following medication from at least 30 days prior to ICF signature:
- •Steroids, oral or parenteral, at a daily dose of = 0.15 mg/kg/day of prednisone or equivalent).
- •Other immunosuppressive drugs (including monoclonal antibodies) or chemotherapy.
- •Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
- •Participated in another clinical study within 30 days prior to ICF signature.
- •Active drug or alcohol abuse or history of drug or alcohol abuse within the 6 months before screening.
- •Direct relative of an employee of the CRO, the study site, or Kedrion.
- •Previously treated under this protocol.
- •Unable to provide informed consent.
- •Patients with any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives or the patient’s participation in this trial.
研究者
相似试验
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)Pediatric Patients Affected by Primary Immunodeficiency Disease.MedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001496-32-SKKEDRION S.P.A30
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)Pediatric Patients Affected by Primary Immunodeficiency DiseaseMedDRA version: 20.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001496-32-ITKEDRION S.P.A30
进行中（未招募）
1 期
Study, in which all know the treatment assigned to the patient, conducted in more sites, to evaluate the efficaty, safety, and metabolism of Kedrion in venous Human Normal Immunoglobulin (IVIg) 10% in child with Primary Immunodeficiency Disease (PID)EUCTR2020-001496-32-PTKEDRION S.P.A30
招募中
1 期
A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery DiseaseMedDRA version: 20.0Level: PTClassification code: 10011078Term: Coronary artery disease Class: 100000004849Coronary Artery DiseaseCTIS2023-506971-89-00Synektik S.A.170
进行中（未招募）
3 期
A clinical study to assess the safety and immunogenicity of Japanese Encephalitis vaccine of BE in 9 to 12 months old infants and in 49-70 year old adultsCTRI/2023/05/053120Biological E.Limited